Clinical and pharmacological group: & nbsp

Antimicrobial, antiparasitic and anthelmintic agents

Included in the formulation
АТХ:

V.03.A   Other different drugs

Pharmacodynamics:

Has the ability to specifically lyse Рroteus vulgaris and Рroteus mirabilis.

Pharmacokinetics:

Not described.

Indications:

Diseases caused by Рroteus vulgaris and Рroteus mirabilis: ENT organs (inflammation of the paranasal sinuses, middle ear, sore throat, pharyngitis, laryngitis); upper and lower respiratory tract (tracheitis, bronchitis, pneumonia, pleurisy); surgical infections (suppuration of wounds, burn, abscess, phlegmon, furuncle, carbuncle, hydroadenitis, panaritium, paraproctitis, mastitis, bursitis, osteomyelitis); urogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingoophoritis); infection gastrointestinal tract and biliary tract (gastroenterocolitis, cholecystitis, dysbiosis); generalized septic diseases; purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis). Prevention of infections caused by Рroteus vulgaris and Рroteus mirabilis (treatment of postoperative and freshly infected wounds). Prevention of nosocomial infections due to epidemic indications.

XI.K80-K87.K85   Acute pancreatitis

X.J00-J06.J03   Acute tonsillitis

X.J00-J06.J02   Acute pharyngitis

X.J00-J06.J01   Acute Sinusitis

XI.K80-K87.K81.1   Chronic cholecystitis

XII.L00-L08.L03   Phlegmon

Contraindications:

Hypersensitivity to the components of the drug.

Carefully:

No data.

Pregnancy and lactation:

Action category for the fetus by Food and Drug Administration (US Food and Drug Administration) - not determined.

The use of this medication during pregnancy and during breast-feeding is possible in the presence of infections caused by phagosensitive strains of bacteria (on the recommendation of a doctor).

Adequate and well-controlled studies on humans and animals have not been conducted. There is no information on the penetration into breast milk.

Dosing and Administration:

Inside, topically, externally, rectally (in the form of microclysters). With diseases gastrointestinal tract, internal organs, dysbacteriosis bacteriophage is administered orally 3 times a day on an empty stomach 1 hour before meals and rectally (in microclyster) 1 time a day instead of one ingestion.

The recommended dose of the drug inside (at 1 reception) and rectally (in the form of microclysters), respectively: children 0-6 months - 5 ml and 10 ml, 6-12 months - 10 ml and 20 ml, 1-3 years - 15 ml and 30 ml, 3-8 years - 20 ml and 40 ml, children older than 8 years and adults - 30 ml and 50 ml.

Locally, externally: in the form of irrigation, lotion and tamponization with a liquid bacteriophage in an amount up to 200 ml, depending on the area of ​​the affected area. When abscesses, the bacteriophage is injected into the cavity of the focus after removal of the pus by puncture. The amount of the drug administered should be somewhat less than the volume of the removed pus. In osteomyelitis after appropriate surgical treatment, a bacteriophage of 10-20 ml is injected into the wound.

In the event that chemical antiseptics were used before the bacteriophage was used to treat wounds, the wound should be thoroughly washed with sterile 0.9% NaCl solution.

Intracavitary injection (in t.ch. pleural, joint and other limited space.): introduced to 100 mL of the bacteriophage, and then allowed to drain capillary, through which a few days reintroduced bacteriophage.

Cystitis, pyelonephritis, urethritis drug is taken orally and if the cavity of the bladder or the renal pelvis drained, bacteriophage introduced through tsistostomu nephrostomy or 1-2 times a day for 20-50 ml into the bladder and in kidney 5-7 ml pelvis.

With purulent-inflammatory gynecological diseases, the drug is injected into the vagina or uterus cavity at a dose of 5-10 ml once daily.

With purulent-inflammatory diseases of the ENT organs for rinsing, rinsing, instillation, administration of moistened turundum (leaving them for 1 h), the drug is administered in a dose of 2-10 ml 1-3 times a day.

Sepsis, enterocolitis of newborns, including premature infants: a bacteriophage is used in the form of high enemas (through a gas outlet tube or catheter) 2-3 times a day. In the absence of vomiting and regurgitation, the use of the drug inside. In this case, it is mixed with breast milk. A combination of rectal (in enemas) and oral administration of the drug is possible. The course of treatment is 5-15 days. With a recurring course of the disease, repeated courses of treatment are possible. In order to prevent sepsis and enterocolitis with intrauterine infection or the danger of nosocomial infection in newborns, the bacteriophage is used as an enema 2 times a day for 5-7 days.

In the treatment of omphalitides, pyoderma, infected wounds, the drug is applied twice daily (gauze is moistened with a bacteriophage and applied to the umbilical wound or to the affected area of ​​the skin).

Treatment of purulent-inflammatory diseases with localized lesions shouldbe performed concomitantly both topically and orally for 7-20 days (according to clinical indications).

Side effects:

Reactions to the drug have not been established.

Overdose:

Not described.

Interaction:

The use of a bacteriophage does not exclude the use of other antibacterial drugs.

Special instructions:

It is not suitable for use in cases of turbidity, presence of flakes, absence of marking and expired shelf life.

An important condition for effective phage therapy is the preliminary determination of the pathogenicity of the pathogen.

Instructions
Up